Insulin delivery using an automated close-loop system significantly improves glycaemic control compared with conventional insulin injection among hospitalized patients with type 2 diabetes (T2D) receiving noncritical care, without increasing the risk of hypoglycaemia, according to a study presented at ADA 2018.
A novel formulation of the GLP-1* receptor agonist semaglutide in oral form led to clinically meaningful HbA1c reduction and weight loss at 26 weeks in patients with type 2 diabetes (T2D) uncontrolled on diet and exercise, according to the PIONEER-1** trial presented at ADA 2018.
The addition of the sodium-glucose linked transporter-2 inhibitor ipragliflozin to insulin resulted in more body weight and fat mass reduction as well as better glucose control than insulin alone in patients with type 2 diabetes (T2D) with weight gain issues, according to a Japanese trial presented at ADA 2018.
Individuals with diabetes who have experienced a recent episode of acute coronary syndrome (ACS) derive the greatest reduction in risk of subsequent major adverse cardiac events (MACE) when given a combination of the PCSK9* inhibitor alirocumab and high-intensity statins compared with individuals with prediabetes or normoglycaemia, according to results of the ODYSSEY OUTCOMES** trial.
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.